Trending Topics in Gastroenterology | GastroAGI

Targeting Hepatic Stellate cells in MASH

Targeting hepatic stellate cells (HSCs) in metabolic dysfunction-associated steatohepatitis (MASH) represents a promising therapeutic approach to prevent or reverse liver fibrosis, a key driver of disease progression. Below is a detailed explanation of the context, mechanisms, and therapeutic strategies derived from the study: ### 1. **Role of Hepatic Stellate Cells in Fibrosis**: - **HSC Activation**: In healthy livers, HSCs exist in a quiescent state (Q), storing vitamin A and maintaining normal extracellular matrix (ECM) turnover. However, in MASH, chronic liver injury caused by metabolic dysfunction (e.g., lipotoxicity, inflammation) triggers HSC transdifferentiation into activated myofibroblast-like cells. - **Fibrogenic Myofibroblasts**: Once activated, HSCs (A1 and A2 phenotypes) proliferate and secrete fibrotic ECM components like collagen and fibronectin. This excessive ECM deposition leads to liver scarring (fibrosis), which impairs liver function and contributes to disease progression. ### 2. **Key Findings from the Study**: - **HSC Subpopulations**: The study identified four distinct HSC phenotypes—quiescent (Q), activated (A1 and A2), and inflammatory (INF). Activated HSCs (A1 and A2) were found to dominate in MASH livers, constituting 13–20% of total liver cells compared to only 4–8% in normal livers. - **Core Fibrogenic Genes**: Six genes—**SERPINE1, GAS7, SPON1, LTBP2, KLF9, and EFEMP1**—were identified as a core fibrogenic gene set driving HSC activation and fibrosis. These genes were upregulated and showed enhanced chromatin accessibility in activated HSCs. - **Pathway Enrichment**: These genes are involved in ECM organization and actin filament regulation, essential for fibrotic scar formation and HSC activation. - **RUNX1/2–SERPINE1 Axis**: The study discovered that the **RUNX1/2-SERPINE1 signaling axis** is a pivotal regulatory pathway promoting HSC activation and ECM deposition, making it a key therapeutic target. ### 3. **Therapeutic Strategies for Targeting HSCs**: - **Targeting SERPINE1 (PAI-1)**: - SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a protein that promotes ECM accumulation and fibrosis. - **Knockdown of SERPINE1** in 3D human MASH liver spheroid models using dicer-substrate siRNA (dsiRNA) significantly reduced fibrogenic marker expression (e.g., COL1A1, ACTA2, TIMP1). - In **in vivo mouse models**, genetic deletion or pharmacologic inhibition of PAI-1 protected against fibrosis induced by liver injury (e.g., CCl₄ or a western diet). - Blocking PAI-1 also inhibited TGFβ-driven fibrotic signaling, suggesting its potential as a therapeutic target. - **Targeting SPON1 and LTBP2**: - Silencing SPON1 and LTBP2 suppressed TGFβ signaling and ECM protein expression, confirming their roles in HSC activation and fibrogenesis. - **Epigenetic Modulation**: - Chromatin accessibility correlated strongly with the activation of fibrogenic genes. Targeting epigenetic regulators that maintain open chromatin at fibrogenic gene loci could prevent HSC activation. - **Transcription Factor Inhibition**: - The study highlighted three classes of transcription factors (TFs) regulating HSC activation: - **Lineage-specific TFs**: JUNB/AP-1. - **Cluster-specific TFs**: RUNX1/2. - **Signal-specific TFs**: FOXA1/2. - Disrupting the crosstalk between RUNX1/2 and FOXA1/2 could block the integration of mechanical (ECM) and cytokine (TGFβ) signals into fibrogenic transcriptional outputs. - **TGFβ Pathway Inhibition**: - TGFβ signaling is a major driver of HSC activation and fibrosis. Therapeutics targeting TGFβ signaling (e.g., inhibitors of TGFβ receptors or downstream effectors) could effectively reduce fibrosis. ### 4. **Validation of Therapeutic Targets**: - **Functional Validation**: - Knockdown of SERPINE1 in human MASH liver spheroids reduced fibrogenic markers, demonstrating its functional role in fibrosis. - **In Vivo Validation**: - In mouse models, genetic deletion or pharmacologic inhibition of PAI-1 prevented fibrosis under various liver injury conditions. - **Cross-Species Validation**: - The identified HSC subclusters and fibrogenic signatures in humans were closely mirrored in murine MASH models, highlighting the translational relevance of these findings. ### 5. **Mechanistic Insights**: - **Epigenetic Priming**: - Activation-associated genes in HSCs were epigenetically primed through open chromatin in promoter and enhancer regions, enabling rapid transcriptional responses to fibrogenic signals. - **Transcriptional Pseudotime Analysis**: - Trajectory analysis revealed a stepwise progression of HSCs from quiescent (Q) to activated states (A1 → A2), with the gradual acquisition of fibrogenic gene signatures. - **RUNX1/2 and FOXA1/2 Crosstalk**: - Mechanistic modeling suggested direct interaction between RUNX1/2 and FOXA1/2, integrating ECM and cytokine signals into fibrogenic transcriptional outputs. ### 6. **Therapeutic Potential**: - The study underscores the potential of targeting the RUNX1/2–SERPINE1 axis or downstream fibrogenic genes (e.g., SPON1, LTBP2, GAS7) as antifibrotic strategies in MASH. - By combining transcriptomic, epigenomic, and functional assays, the study provided a comprehensive understanding of HSC activation dynamics and identified concrete druggable pathways. ### 7. **Conclusion**: - Targeting hepatic stellate cells in MASH offers a promising therapeutic strategy to combat liver fibrosis. The identification of key regulatory pathways (e.g., RUNX1/2–SERPINE1 axis) and fibrogenic genes (e.g., SPON1, LTBP2) provides a solid foundation for developing antifibrotic therapies. - Future therapies could involve small-molecule inhibitors, RNA-based therapeutics (e.g., siRNA), or monoclonal antibodies targeting these pathways to prevent or reverse fibrosis in metabolic liver disease.

Plasma metabolomics prevents MASH related mortality

Plasma metabolomics, a branch of metabolomics focused on analyzing small molecules (metabolites) in blood plasma, plays a promising role in the prevention of metabolic dysfunction-associated steatohepatitis (MASH) and related liver mortality. This approach focuses on identifying biochemical changes and patterns in the blood that are linked to liver dysfunction, allowing for early detection, risk stratification, and targeted interventions. Below is a detailed explanation of how plasma metabolomics contributes to MASH prevention and mortality reduction: ### 1. **Understanding Plasma Metabolomics** - **Definition**: Plasma metabolomics involves the study of metabolites—small molecules such as lipids, amino acids, and carbohydrates—in blood plasma. These metabolites reflect ongoing physiological and pathological processes in the body. - **Tools**: Techniques like nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) are commonly used to analyze the metabolome in a cost-effective and scalable manner. - **Clinical Relevance**: Plasma metabolomics provides insights into systemic metabolic health, making it a valuable tool for understanding and managing metabolic disorders, including MASH. ### 2. **Role of Plasma Metabolomics in MASH Prevention** - **Early Detection**: Metabolomic profiling can identify biomarkers associated with liver dysfunction, such as elevated levels of tyrosine and specific lipid ratios (e.g., the phospholipids-to-total lipids ratio in very-low-density lipoproteins [V0PLp]). These biomarkers can detect MASH at an early stage before significant liver damage occurs. - **Risk Prediction**: By developing metabolome-derived scores (like the one created by Huang et al.), plasma metabolomics can accurately predict individuals at high risk of developing MASH or experiencing liver-related mortality. - **Personalized Interventions**: Identifying specific metabolic abnormalities allows clinicians to tailor interventions, such as dietary changes, weight management, or pharmacological treatments, to prevent disease progression. - **Monitoring Disease Progression**: Plasma metabolomics can be used to track changes in metabolic profiles over time, helping clinicians assess the effectiveness of interventions and adjust treatment strategies accordingly. ### 3. **Reducing MASH-Related Mortality** - **Prognosis and Outcome Prediction**: Plasma metabolomics-based scores have demonstrated high predictive accuracy for liver-related mortality. For example, Huang et al.'s model achieved AUROC values of 0.88 and 0.93 for MASLD-related mortality in validation cohorts, suggesting strong potential for identifying patients at risk of severe outcomes. - **Targeted Management**: By identifying at-risk individuals, healthcare providers can implement early and aggressive management strategies to prevent complications such as cirrhosis, liver failure, or hepatocellular carcinoma, which are major contributors to liver-related mortality. - **Mechanistic Insights**: Plasma metabolomics can provide a better understanding of the biochemical pathways involved in MASH and its progression, paving the way for novel therapeutic targets. ### 4. **Key Biomarkers in Plasma Metabolomics for MASH** - **Tyrosine**: Elevated plasma tyrosine levels have been consistently associated with liver dysfunction and long-term liver-related events. This aligns with prior evidence linking tyrosine to metabolic and inflammatory pathways relevant to MASH. - **Phospholipids-to-Total Lipids Ratio in V0PLp**: This novel biomarker captures lipid metabolism abnormalities associated with liver disease. While its exact biological role in MASH is not yet fully understood, it has shown strong predictive utility in Huang et al.'s model. - **Other Metabolites**: Additional metabolites, such as amino acids, bile acids, and lipid species, may also serve as potential biomarkers for MASH and liver-related outcomes. ### 5. **Advantages of Plasma Metabolomics** - **Non-Invasive**: Plasma metabolomics relies on blood samples, making it minimally invasive and more acceptable to patients compared to liver biopsies. - **Cost-Effective**: Techniques like NMR-based metabolomics are relatively affordable, enabling large-scale implementation in clinical settings. - **Scalability**: Plasma metabolomics can be integrated into routine clinical workflows, allowing for widespread screening and monitoring of at-risk populations. ### 6. **Challenges and Limitations** - **Validation Across Populations**: The predictive models need to be validated in diverse populations to ensure generalizability across ethnicities, disease etiologies, and healthcare settings. - **Mechanistic Understanding**: The biological rationale behind certain biomarkers, such as the V0PLp ratio, remains unclear and requires further research to strengthen confidence in their use. - **Clinical Utility**: While plasma metabolomics shows promise, its net diagnostic and clinical benefits in real-world settings have yet to be quantified. Decision curve analysis and other tools are needed to assess its impact on patient care. - **Standardization and Accessibility**: Translating metabolomics-based biomarkers into routine clinical practice requires standardized protocols, accessible technology, and trained personnel. ### 7. **Future Directions** - **Longitudinal Studies**: Further research is needed to evaluate how metabolomic profiles change over time and how these changes correlate with disease progression and outcomes. - **Integration with Other Biomarkers**: Combining plasma metabolomics with other diagnostic tools, such as imaging or genetic testing, could enhance predictive accuracy and clinical utility. - **Focus on Prevention**: By identifying individuals at risk of MASH early, plasma metabolomics could shift the focus from treatment to prevention, reducing the burden of liver-related mortality. ### 8. **Conclusion** Plasma metabolomics represents a transformative approach to preventing MASH and related mortality. By identifying and leveraging specific metabolic biomarkers, clinicians can detect MASH early, predict disease outcomes, and implement personalized interventions. However, challenges related to validation, standardization, and clinical utility must be addressed before metabolomics-based tools can be widely adopted in clinical practice. Despite these challenges, the integration of plasma metabolomics into healthcare holds great promise for advancing precision medicine in chronic liver disease management.

Exosome-related genes for MASLD-related HCC

Exosome-related genes have gained significant attention for their potential role in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD) to hepatocellular carcinoma (HCC). These genes are involved in the biogenesis, secretion, and function of exosomes, which are small extracellular vesicles that mediate intercellular communication. Below is a detailed explanation of the role of exosome-related genes in MASLD-related HCC: --- ### **What are Exosome-Related Genes?** Exosome-related genes are those involved in the biogenesis, secretion, and function of exosomes. Exosomes are vesicles released by cells that carry bioactive molecules such as proteins, lipids, and RNA. They are critical in intercellular communication and influence various biological processes, including immune responses, inflammation, and tumor progression. In the context of MASLD-related HCC, exosome-related genes regulate the secretion and content of exosomes, which can influence the tumor microenvironment, immune modulation, and metabolic reprogramming. --- ### **Role of Exosome-Related Genes in MASLD (NAFLD)** 1. **Progression from MASLD to HCC:** - MASLD is a metabolic liver disorder characterized by fat accumulation in the liver. It can progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and eventually HCC. - Exosome-related genes play a role in this progression by influencing intercellular signaling pathways that promote inflammation, fibrosis, and oncogenesis. 2. **Exosome-Mediated Communication:** - Exosomes facilitate communication between hepatocytes, immune cells, and the tumor microenvironment. This signaling can exacerbate liver damage, promote fibrosis, and create a pro-tumorigenic microenvironment. - For example, exosome cargo such as microRNAs (miRNAs) and proteins can activate pathways that drive inflammation and metabolic dysregulation in MASLD. 3. **Biomarker Potential:** - Exosome-related genes and the exosomes they regulate are being studied as non-invasive biomarkers for MASLD progression. They can help identify patients at risk of developing HCC from MASLD. --- ### **Correlation Between HCC and MASLD** 1. **MASLD as a Major Risk Factor for HCC:** - MASLD is one of the leading causes of HCC, especially in the absence of other risk factors such as viral hepatitis or alcohol abuse. - Chronic inflammation, oxidative stress, and metabolic dysregulation in MASLD create a favorable environment for hepatocarcinogenesis. 2. **Exosome-Driven Tumor Microenvironment:** - Exosomes derived from MASLD-affected hepatocytes can carry oncogenic signals, such as pro-inflammatory cytokines, miRNAs, and other molecules, which promote tumor initiation and progression. - Exosome-related genes contribute to this process by regulating the secretion of tumor-promoting exosomes. 3. **Immunomodulation:** - Exosome-related genes influence immune cell activity in MASLD and HCC. For example, exosomes can suppress anti-tumor immune responses by modulating T-cell activity and promoting immune checkpoint expression. --- ### **Exosome-Related Genes and MASLD-HCC Progression** A recent study identified three key exosome-related genes—**VPS45**, **VAMP5**, and **EXPH5**—that play a critical role in MASLD-HCC progression. These genes were used to construct a diagnostic and prognostic model for MASLD-HCC. 1. **VPS45 (Vacuolar Protein Sorting 45):** - Involved in the trafficking and secretion of exosomes. - High expression of VPS45 was observed in MASLD-HCC patients and was associated with increased immune cell infiltration and tumor progression. 2. **VAMP5 (Vesicle-Associated Membrane Protein 5):** - Plays a role in exosome biogenesis and vesicle transport. - Elevated VAMP5 expression correlated with poor prognosis and increased CD4⁺ T-cell infiltration in MASLD-HCC patients. 3. **EXPH5 (Exophilin 5):** - Regulates exosome secretion and cargo sorting. - Unlike VPS45 and VAMP5, EXPH5 expression was decreased in MASLD-HCC, suggesting a potential tumor-suppressive role. --- ### **How These Genes Influence MASLD-HCC** 1. **Diagnostic and Prognostic Value:** - A logistic regression model using VPS45, VAMP5, and EXPH5 was developed to predict MASLD-HCC progression: - **Risk score formula:** Risk score = 1/(1 + e⁻ᶻ), where Z = 1.238×VPS45 + 1.239×VAMP5 − 1.455×EXPH5 − 11.047. - This model achieved high diagnostic accuracy with an area under the curve (AUC) of 0.736 for distinguishing MASLD-HCC from non-tumor liver tissues. 2. **Immune Microenvironment Modulation:** - High-risk patients (based on the gene signature) showed increased infiltration of memory CD4⁺ T-cells but reduced expression of immune checkpoint molecules such as PD1, PDL1, and PDL2. This suggests an altered immune microenvironment that may contribute to immunotherapy resistance. 3. **Metabolic Reprogramming:** - Pathway enrichment analysis revealed that exosome-related genes are involved in metabolic pathways such as "carbon metabolism" and "drug metabolism–cytochrome P450," which are critical in tumorigenesis. 4. **Therapeutic Implications:** - High-risk MASLD-HCC patients showed greater sensitivity to certain chemotherapeutic agents (e.g., 5-fluorouracil, cisplatin, irinotecan), suggesting that the gene signature could guide personalized treatment strategies. --- ### **Key Findings and Clinical Implications** 1. **Non-Invasive Biomarkers:** - The VPS45–VAMP5–EXPH5 gene signature offers a non-invasive molecular tool for diagnosing and stratifying MASLD-HCC patients, improving early detection. 2. **Prognostic Value:** - High-risk patients identified by the gene signature had significantly worse overall survival, making it a reliable prognostic biomarker. 3. **Link to TP53 Mutations:** - High-risk MASLD-HCC patients had a higher prevalence of TP53 mutations, suggesting a link between exosome secretion regulation and TP53-driven oncogenesis. 4. **Potential for Precision Oncology:** - The study highlights the potential of combining exosome-related gene signatures with immunotherapy and chemotherapy for personalized treatment of MASLD-HCC. --- ### **Conclusion** Exosome-related genes, particularly VPS45, VAMP5, and EXPH5, play a pivotal role in the progression of MASLD to HCC. These genes influence exosome secretion, immune modulation, and metabolic reprogramming, making them valuable biomarkers and therapeutic targets. The development of a gene-based diagnostic and prognostic model represents a significant step forward in precision oncology for MASLD-HCC, offering new opportunities for early detection and personalized treatment strategies.

Normal ALT, Liver Fibrosis and MASLD

The study you provided investigates the relationship between normal ALT (alanine transaminase) levels, liver fibrosis, and metabolic dysfunction-associated steatotic liver disease (MASLD). Here's a detailed breakdown of the findings and implications for patients with normal ALT levels and liver fibrosis in the context of MASLD: --- ### **Key Insights:** 1. **Definition of Normal ALT in MASLD Patients:** - Persistently normal ALT levels were defined as three consecutive ALT measurements within the normal range over six months: - **Men:** <33 IU/L - **Women:** <25 IU/L - Elevated ALT levels were considered above these thresholds. 2. **Fibrosis Risk in Normal ALT Patients:** - Despite having normal ALT levels, MASLD patients can still have significant liver fibrosis. - Normal ALT levels may give a false impression of clinical stability, underestimating the risk of fibrosis progression. 3. **Fibrosis Regression in Normal ALT Patients:** - Compared to patients with elevated ALT and fibrosis, those with normal ALT and fibrosis showed **poorer fibrosis regression rates** (31.9% vs. 53.4%, p = 0.001). - This indicates that fibrosis in normal ALT patients is less likely to improve with lifestyle interventions. 4. **Lifestyle Intervention Requirements:** - Patients with normal ALT and fibrosis required **greater weight loss** and **steatosis reduction** to achieve fibrosis regression compared to those with elevated ALT: - **Weight Loss Threshold:** - 8.55% in normal ALT/fibrosis patients. - 4.94% in elevated ALT/fibrosis patients. - **Liver Fat Content (LFC) Reduction Threshold:** - 39.85% in normal ALT/fibrosis patients. - 20.57% in elevated ALT/fibrosis patients. - This suggests that patients with normal ALT may need more aggressive lifestyle changes to achieve similar outcomes. 5. **Mechanistic Explanation:** - **Normal ALT Levels:** - May reflect quiescent hepatic stellate cells (HSCs) and reduced macrophage activation. - This limits collagen degradation and fibrosis reversal, making fibrosis regression more difficult. - **Elevated ALT Levels:** - Associated with active hepatocyte repair and extracellular matrix remodeling. - This explains why fibrosis regression is more pronounced in elevated ALT patients. 6. **Inflammation and Fibrosis Improvement:** - Elevated high-sensitivity C-reactive protein (hs-CRP >2.0 mg/L) was linked to greater fibrosis improvement, particularly in normal ALT/fibrosis patients. - This suggests that inflammation may play a role in fibrosis dynamics, even in patients with normal ALT. 7. **Stage-Specific Effects:** - ALT elevation predicted fibrosis regression primarily in early fibrosis stages (F1–F2). - In advanced fibrosis stages (F3–F4), structural liver damage becomes irreversible, and ALT levels were less predictive of improvement. --- ### **Clinical Implications for Normal ALT Patients:** 1. **Aggressive Management Required:** - Patients with MASLD and normal ALT levels, especially those with fibrosis, require **intensified lifestyle interventions** (e.g., stricter caloric restriction and more physical activity). - Pharmacologic treatments may also be needed in these patients to address the higher effort required for fibrosis regression. 2. **Non-Invasive Monitoring:** - Combining MRI-proton density fat fraction (MRI-PDFF) for liver fat content and 2D-shear wave elastography (2D-SWE) for fibrosis provides a reliable, non-invasive alternative to liver biopsy. - These tools can help monitor steatosis and fibrosis changes over time in normal ALT patients. 3. **Risk Awareness:** - Patients with normal ALT levels should not be considered "low risk" for fibrosis progression. - Clinicians should be vigilant in assessing fibrosis status and tailoring interventions accordingly. 4. **Inflammation as a Target:** - Elevated hs-CRP levels in normal ALT patients suggest that targeting systemic inflammation may enhance fibrosis regression. --- ### **Study Limitations:** - Single-center design and predominance of male participants (72%) may limit generalizability. - Self-reported adherence to lifestyle interventions could introduce bias. - Serial ALT trend tracking and biomarkers were not included, which could refine predictive models. --- ### **Conclusion:** MASLD patients with normal ALT levels are at significant risk for liver fibrosis and show poorer fibrosis regression compared to those with elevated ALT. Achieving fibrosis improvement in these patients requires greater weight loss and steatosis reduction, underscoring the need for aggressive management strategies and close monitoring. Non-invasive imaging techniques like MRI-PDFF and 2D-SWE should be utilized for tracking treatment progress, and future research should focus on refining predictive models with multicenter cohorts and advanced biomarkers.

Rapamycin alleviate intrahepatic inflammation in MASLD

Yes, rapamycin alleviates intrahepatic inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). According to the study, rapamycin's therapeutic effects are primarily mediated through its action on bone marrow-derived macrophages, which are key immune cells involved in liver inflammation. Rapamycin suppresses the proinflammatory activation of hepatic macrophages and enhances pathways related to fatty acid oxidation within these cells. By promoting fatty acid oxidation in macrophages, rapamycin reduces their inflammatory capacity, thereby creating a less inflammatory hepatic microenvironment. This reprogramming of macrophage metabolism toward an anti-inflammatory state is a key mechanism by which rapamycin mitigates intrahepatic inflammation in MASLD. Thus, rapamycin offers a promising approach to targeting inflammation in MASLD and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH). However, it is important to note that while rapamycin improves hepatic inflammation, steatosis, and steatohepatitis, it does not have a significant impact on established liver fibrosis.

Fisetin against the development of MAFLD

Fisetin, a natural flavonoid found in fruits and vegetables like strawberries and apples, has shown significant potential in combating metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD, a chronic liver condition linked to obesity, insulin resistance, and type 2 diabetes, affects nearly 30% of the global population. In a study using a high-fat diet (HFD)-induced mouse model and sodium oleate (OA)-treated HepG2 cells, fisetin demonstrated remarkable therapeutic effects against MAFLD progression. Fisetin significantly reduced body weight gain, liver mass, and fat accumulation in HFD-fed mice without altering food intake, indicating metabolic improvement. It improved blood glucose levels, glucose tolerance, and lipid profiles, including lowering triglycerides, total cholesterol, and LDL-C while increasing protective HDL-C levels. Fisetin also enhanced liver function by reducing serum AST and ALT levels, markers of hepatic injury. Histological analyses confirmed reduced hepatic lipid accumulation and increased glycogen storage, reflecting improved glucose utilization and suppressed gluconeogenesis. Fisetin restored antioxidant balance by enhancing superoxide dismutase (SOD) activity and reducing reactive oxygen species (ROS) and nitric oxide (NO) levels. Mechanistically, fisetin activated the GSK-3β/Nrf2/HO-1 pathway, upregulated antioxidant enzymes, and downregulated gluconeogenic enzymes (PEPCK, G6PC), promoting glucose and lipid homeostasis. These findings suggest fisetin as a promising natural therapeutic for MAFLD.

Survodutide - Role in MASH

Survodutide is emerging as a promising treatment for metabolic dysfunction–associated steatohepatitis (MASH), a progressive form of metabolic dysfunction–associated steatotic liver disease (MASLD). Survodutide functions as a dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors, targeting both metabolic and hepatic pathways central to MASH pathology. By activating GLP-1 receptors, Survodutide reduces appetite and improves insulin resistance, while glucagon receptor activation decreases liver fat production, potentially reversing key aspects of MASH. In a 48-week multicenter trial involving 293 patients with biopsy-confirmed MASH, Survodutide demonstrated robust efficacy. Between 43–62% of patients treated with Survodutide achieved histologic resolution of MASH, compared to 14% in the placebo group. Furthermore, over 57% of participants experienced at least a 30% reduction in liver fat, highlighting its strong metabolic and hepatic benefits. These outcomes underscore the drug’s potential in addressing both liver inflammation and fat accumulation, critical drivers of MASH progression. Despite its efficacy, Survodutide’s safety profile revealed notable gastrointestinal adverse effects, including nausea, vomiting, and diarrhea. These side effects led to treatment discontinuation in approximately 20% of patients, significantly higher than the 3% discontinuation rate in the placebo group. Survodutide’s promising results align with findings from tirzepatide, another dual receptor agonist targeting GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Both drugs significantly outperform prior MASH treatments, offering hope for future combination or sequential therapies. However, larger, longer-term studies are needed to confirm Survodutide’s sustained benefits and long-term safety, particularly in diverse patient populations.

Efruxifermin and MASH

Efruxifermin (EFX) is a promising treatment for metabolic dysfunction-associated steatohepatitis (MASH), a severe progression of metabolic liver disease with limited effective therapies. EFX is a fibroblast growth factor 21 (FGF21) analogue that offers dual benefits for both liver and metabolic health. It works by regulating lipids, improving insulin sensitivity, and reducing inflammation. In a systematic review of four phase 2 clinical trials involving 450 participants with biopsy-confirmed MASH, EFX was evaluated for its safety and efficacy. Administered weekly via subcutaneous injection at doses of 28 mg or 50 mg, EFX showed significant improvements in liver health and metabolic parameters over 12 to 96 weeks. EFX reduced liver enzyme levels (ALT, AST, GGT) and hepatic fat fraction (HFF) by 54% to 62%, with some patients achieving complete normalization of liver fat. It also improved liver fibrosis and resolved MASH in many cases. Non-invasive markers of fibrosis, such as ELF scores and liver stiffness, showed notable reductions, confirming its antifibrotic effects. Metabolically, EFX improved HbA1c, insulin resistance, triglycerides, LDL-C, and increased HDL-C and adiponectin. The 50 mg dose led to modest weight loss, while the 28 mg dose focused on metabolic improvements without significant weight changes. Though EFX caused mild-to-moderate gastrointestinal side effects like nausea and diarrhea, it was generally well-tolerated. Compared to other therapies like GLP-1 receptor agonists, EFX demonstrated stronger effects on liver histology and fibrosis. Efruxifermin offers a comprehensive therapeutic approach for MASH, addressing liver, metabolic, and inflammatory aspects, making it a leading candidate for future treatment. Phase 3 trials are ongoing to confirm its long-term benefits.

Rising Global Burden of MASLD

The global burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD, is rising at an alarming rate and poses a significant public health challenge. MASLD is now the most common chronic liver disease worldwide, affecting approximately 1.27 billion people in 2021, with a prevalence rate of 15,018 per 100,000 population. It is closely linked to obesity, type 2 diabetes mellitus (T2DM), and cardiovascular diseases, reflecting its intricate connection with other metabolic disorders. Over the past two decades (2000–2021), MASLD prevalence has increased by 75%, driven by global lifestyle changes, dietary transitions, and rising obesity rates. Although its prevalence has surged, the overall disability burden (measured in disability-adjusted life years or DALYs) has remained relatively stable compared to other metabolic diseases. However, significant regional disparities exist. The Eastern Mediterranean region has the highest MASLD prevalence, while the Americas bear the greatest disability burden. Middle-income countries, particularly in low-middle socioeconomic strata, experience the highest burden due to limited healthcare access and preventive measures. Sex-based differences reveal that males face a higher overall burden, but the rate of increase in MASLD is slightly higher in females. The pandemic has likely exacerbated this burden through sedentary lifestyles and disrupted healthcare services. MASLD is intricately linked with other metabolic diseases like T2DM and obesity, acting as both a consequence and a risk amplifier. Urgent public health efforts, such as lifestyle interventions, early screening, and better healthcare access, are needed to address this escalating global crisis. Recognizing MASLD as a major public health threat is critical for reducing its impact.

Spleen-To-Liver Stiffness Ratio in MASH

The spleen-to-liver stiffness ratio (SSM/LSM) is an emerging noninvasive biomarker that has shown significant potential in characterizing portal hypertension (PH), particularly in patients with metabolic dysfunction-associated steatohepatitis (MASH). Here is a detailed breakdown of the findings related to SSM/LSM in MASH based on the context provided: --- ### **1. Key Observations:** - **Higher SSM/LSM Ratio in MASH:** Patients with MASH exhibited a significantly higher spleen-to-liver stiffness ratio (median 1.66) compared to patients with alcohol-related liver disease (ALD) (median 1.28, p = 0.001). This suggests that spleen stiffness increases disproportionately relative to liver stiffness in MASH. - **Comparison to PSVD:** MASH values approached those seen in porto-sinusoidal vascular disease (PSVD), which had the highest SSM/LSM ratio (median 3.19). This supports the hypothesis that MASH includes a presinusoidal component of PH, similar to PSVD. - **Independence from Comorbidities:** After adjusting for factors like body mass index (BMI), diabetes, hypertension, and statin use, MASH remained an independent predictor of a higher SSM/LSM ratio (β = 0.59, p = 0.046). This indicates that the elevated ratio is specific to the vascular characteristics of MASH and not merely a result of metabolic comorbidities. --- ### **2. Clinical and Mechanistic Insights:** - **Presinusoidal Component in MASH:** The elevated SSM/LSM ratio in MASH reflects a presinusoidal component of PH that is not captured by traditional hepatic venous pressure gradient (HVPG) measurements. This presinusoidal PH is likely due to periportal vascular injury, ductular reaction, and portal fibrosis, which elevate splenic pressure independently of sinusoidal resistance. - **Early Detection of Portal Hypertension:** MASH patients exhibited higher SSM/LSM ratios even at lower HVPG levels, suggesting that the spleen stiffness-to-liver stiffness relationship could serve as an early indicator of portal venous pressure elevation before significant hepatic fibrosis develops. This is crucial for early detection and management of PH in MASH. - **Spleen Size Correlation:** Despite having less severe liver disease (lower MELD and HVPG scores), MASH patients had equal or slightly larger spleen diameters compared to ALD patients. When adjusted for HVPG, spleen size per pressure unit was significantly greater in MASH (1.15 cm/mmHg vs. 0.85 cm/mmHg, p < 0.001), further highlighting the presinusoidal vascular changes in MASH. --- ### **3. Prognostic Implications:** - **Risk of Hepatic Decompensation:** Patients with MASH and higher SSM/LSM ratios demonstrated a numerically higher risk of hepatic decompensation (13–18% at 6–12 months) compared to those with lower ratios. Although not statistically significant (p = 0.67), this suggests potential prognostic value for SSM/LSM in identifying patients at greater risk of complications. - **Distinct Hemodynamic Patterns:** The inverse correlation between the SSM/LSM ratio and HVPG (R = −0.35) indicates that as presinusoidal PH increases, the ratio rises despite lower HVPG values. This confirms the distinct hemodynamic patterns in MASH compared to other liver disease etiologies. --- ### **4. Comparison Between MASH and ALD:** - **Different PH Mechanisms:** ALD patients showed more severe intrahepatic fibrosis (higher LSM values), while MASH patients had greater extrahepatic pressure gradients (higher SSM/LSM ratios). This reinforces the idea that MASH and ALD have different mechanisms of portal hypertension, with MASH being more influenced by presinusoidal vascular changes. - **Correlation with HVPG:** While both LSM and SSM correlated significantly with HVPG across all etiologies (R = 0.54 and 0.42, respectively), the correlation was stronger in MASH (R = 0.62 for LSM and 0.55 for SSM). This indicates that these metrics are particularly effective in tracking PH severity in MASH. --- ### **5. Potential as a Noninvasive Biomarker:** The SSM/LSM ratio has the potential to serve as a novel imaging biomarker for identifying MASH patients with early or mixed-type PH. This could reduce reliance on invasive HVPG testing and provide a more comprehensive understanding of portal dynamics in metabolic liver disease. --- ### **6. Limitations and Future Directions:** - **Small MASH Sample Size:** The study included only 49 MASH patients, which limits the generalizability of the findings. Larger cohorts are needed to validate the results. - **Lack of Histological Validation:** The study did not include histological confirmation of presinusoidal fibrosis, which would strengthen the mechanistic insights. - **Absence of Direct Portal Pressure Measurements:** While HVPG is the gold standard for measuring portal pressure, it does not adequately capture presinusoidal PH. Future studies could incorporate direct portal pressure measurements to better understand the relationship between SSM/LSM and PH. --- ### **7. Conclusion:** The spleen-to-liver stiffness ratio (SSM/LSM) is a valuable noninvasive marker for detecting presinusoidal components of portal hypertension in MASH. It highlights unique vascular characteristics in MASH, such as early portal venous pressure elevation and splenomegaly, which are not captured by traditional HVPG measurements. This ratio could enhance the diagnosis, risk stratification, and management of portal hypertension in metabolic liver disease, marking a shift toward more precise, etiology-specific assessment of portal dynamics.